Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
Explore this paper's citation graph
- Type
- article
- Published
- 2012-01-01
- Cited by
- 276
- References
- 39
- Access
- Open access
- OpenAlex
- https://openalex.org/W1584669207
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6068818
Keywords
Medicine, Response Evaluation Criteria in Solid Tumors, Hepatocellular carcinoma, Sorafenib, Progressive disease
References
- Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings.
- Phase 1‐2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
- Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- Post-treatment imaging of liver tumours
- Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
- Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma
- Change in contrast enhancement of HCC on 1-month follow-up CT after local radiotherapy: an early predictor of final treatment response.
- The Agreement between Competing Imaging Measures of Response of Hepatocellular Carcinoma to Yttrium-90 Radioembolization
- 583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA
- Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
- Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
- Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- Treatment of Unresectable Primary and Metastatic Liver Cancer with Yttrium-90 Microspheres (TheraSphere®): Assessment of Hepatic Arterial Embolization
Cited by
- Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations
- Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature.
- Chemoembolization and Radioembolization for Hepatocellular Carcinoma
- Comparison of RECIST, mRECIST, and Choi Criteria for Early Response Evaluation of Hepatocellular Carcinoma After Transarterial Chemoembolization Using Drug-Eluting Beads
- Applications d'une modulation pharmacologique des dérives des formes réactives de l'oxygène pour une optimisation thérapeutique des patients traités par chimiothérapie
- The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
- Evaluation of Sorafenib therapy in hepatocellular carcinoma
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma
- Estudio de utilización de microesferas DC Bead® cargadas con doxorubicina para quimioembolización hepática del hepatocarcinoma
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
- Treating advanced hepatocellular carcinoma: How to get out of first gear
- Chimioembolisation et hépatocarcinome: pour quel type de patient ?
- Carcinoma hepatocelular: diagnóstico y tratamiento
- Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
- Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
- Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
- Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today?
- Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
- Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization.
Related papers
- Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma
- High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Sorafenib in hepatocellular carcinoma.
- Data from High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Supplementary Methods from SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
- 進行肝細胞癌患者に対する分子標的薬（ソラフェニブ）投与における治療効果判定基準の比較